

EP06

Evaluation of Linearity of Quantitative Measurement Procedures

This guideline provides information for characterizing the linearity interval of a measurement procedure, validating a linearity interval claim (to be performed by the manufacturer), and verifying an established linearity interval claim (to be performed by the end user).

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Evaluation of Linearity of Quantitative Measurement Procedures

Robert J. McEnroe, PhD
A. Paul Durham, MA
Marina V. Kondratovich, PhD
Jesper V. Johansen, PhD

Patrick G. Meyers, MS, CQE
Rhona J. Souers, MS
Jeffrey E. Vaks, PhD

Abstract

Clinical and Laboratory Standards Institute guideline EP06—*Evaluation of Linearity of Quantitative Measurement Procedures* is intended to provide both manufacturers and users of quantitative measurement procedures with an economical and user-friendly method of validating and verifying the linearity interval. This guideline also can be used to determine the extent to which a quantitative measurement procedure meets medical requirements or the manufacturer's linearity interval claims.

Clinical and Laboratory Standards Institute (CLSI). *Evaluation of Linearity of Quantitative Measurement Procedures*. 2nd ed. CLSI guideline EP06 (ISBN 978-1-68440-096-6 [Print]; ISBN 978-1-68440-097-3 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2020.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@clsi.org **W:** www.clsi.org

Copyright ©2020 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Evaluation of Linearity of Quantitative Measurement Procedures*. 2nd ed. CLSI guideline EP06. Clinical and Laboratory Standards Institute; 2020.

Previous Editions:

October 1986, December 2001, April 2003

EP06-Ed2

ISBN 978-1-68440-096-6 (Print)

ISBN 978-1-68440-097-3 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 40, Number 16

.....

Committee Membership

Consensus Council

James R. Petisce, PhD
Chairholder
BD Diagnostic Systems
USA

Collette Fitzgerald, PhD
 Centers for Disease Control and
 Prevention
 USA

M. Laura Parnas, PhD, DABCC
 Roche Diagnostics
 USA

Mary Lou Gantzer, PhD, FACB
Vice-Chairholder
USA

Loralie J. Langman, PhD, DABCC, FACB,
 F-ABFT
 Mayo Clinic
 USA

Robert Rej, PhD
 New York State Department
 of Health – Wadsworth Center
 USA

Anne T. Daley, MS, MT(ASCP)DLM,
 CMQ/OE(ASQ)CSBB
 ARUP Laboratories
 USA

Michelle McLean, MS, MT(ASCP), BS
 Greiner Bio-One, Inc.
 USA

Matthew A. Wikler, MD, FIDSA, MBA
 IDTD Consulting
 USA

Avis Danishefsky, PhD
 FDA Center for Devices and
 Radiological Health
 USA

Tania Motschman, MS, MT(ASCP)SBB
 Laboratory Corporation of America
 USA

Document Development Committee on Evaluation of Linearity

Robert J. McEnroe, PhD
Chairholder
USA

A. Paul Durham, MA
 APD Consulting
 USA

Patrick G. Meyers, MS, CQE
 Abbott
 USA

Edward Blackman, MD
 Los Robles Regional Medical Center
 USA

Marina V. Kondratovich, PhD
 FDA Center for Devices and
 Radiological Health
 USA

Rhona J. Souers, MS
 College of American Pathologists
 USA

Susan J. Danielson, PhD
 Ortho-Clinical Diagnostics, Inc.
 USA

Staff

Clinical and Laboratory Standards
 Institute
 USA

Megan L. Tertel, MA, ELS
Editorial Manager

Kristy L. Leirer, MS
Editor

David E. Sterry, MT(ASCP)
Project Manager

Catherine E.M. Jenkins
Editor

Laura Martin
Editor

Tabitha Kern, MS, MLS(ASCP)^{CM}
Project Manager

Acknowledgment for the Expert Panel on Evaluation Protocols

CLSI, the Consensus Council, and the Document Development Committee on Evaluation of Linearity gratefully acknowledge the Expert Panel on Evaluation Protocols for serving as technical advisors and subject matter experts during the revision of this guideline.

Expert Panel on Evaluation Protocols

Paula Ladwig, MS, MT(ASCP)
Chairholder
Mayo Clinic
USA

Jeffrey R. Budd, PhD
 USA

Stephen Lovell, BS, PhD
 FDA Center for Devices and
 Radiological Health
 USA

James H. Nichols, PhD, DABCC, FAACB
Vice-Chairholder
Vanderbilt University School
of Medicine
USA

A. Paul Durham, MA
 APD Consulting
 USA

Nancy S. Miller, MD
 Boston University School of Medicine
 USA

Valeria L. Alcon, PhD
 Health Canada
 Canada

Brett Holmquist, PhD, ASCP, DABCC,
 FAACC
 LabCorp - Endocrine Sciences
 USA

Jeffrey E. Vaks, PhD
 Roche Molecular Diagnostics
 USA

J. Rex Astles, PhD, DABCC, FAACC
 Centers for Disease Control and
 Prevention
 USA

Jesper V. Johansen, PhD
 Radiometer Medical ApS
 Denmark

Edward Ki Yun Leung, PhD, DABCC,
 FAACB
 Children's Hospital Los Angeles
 USA

Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Evaluation of Linearity gratefully acknowledge the following volunteers for their important contributions to the revision of this guideline:

Jesper V. Johansen, PhD
 Radiometer Medical ApS
 Denmark

Joseph Passarelli
 Roche Diagnostics
 USA

Jeffrey E. Vaks, PhD
 Roche Molecular Diagnostics
 USA

Contents

Abstract	i
Committee Membership	iii
Foreword	vii
Chapter 1: Introduction	1
1.1 Scope	2
1.2 Background	2
1.3 Standard Precautions	4
1.4 Terminology	4
Chapter 2: General Considerations for Measurement Procedure Linearity	11
2.1 Process Flow Chart	12
2.2 Introduction	13
2.3 Advantages of a Linear Measurement Procedure	14
2.4 Linearity of the Measurement Procedure and Calibration	14
2.5 Linearity vs Modeling of the Calibration Relationship	17
2.6 Relationship Between Linearity and Trueness	17
2.7 Relationship Between Linearity Interval and Analytical Measuring Interval	18
2.8 Two Basic Designs of the Linearity Study	18
2.9 Establishing Study Goals	22
2.10 Developing a Measurement Procedure	24
Chapter 3: Validating the Measurement Procedure Linearity Interval	25
3.1 Introduction to Validating the Linearity Interval	26
3.2 Preparing a Sample Panel for the Linearity Study	28
3.3 Study Designs	34
3.4 Preparing Linearity Panel Samples	38
3.5 Testing the Linearity Panel Samples	43
3.6 Data Analysis	47
3.7 Recommendations for Stating a Performance Claim for the Linearity Interval	60
3.8 Special Considerations	60
Chapter 4: Verifying the Measurement Procedure Linearity Interval	63
4.1 Introduction to Verifying the Linearity Interval	64
4.2 Samples and Preparation	66
4.3 Study Procedure	69
4.4 Inspection for Data Integrity	69

Contents (Continued)

4.5 Data Analysis: Weighted Least Squares Regression Analysis With Confidence Intervals	70
4.6 Alternative Data Analysis Options	78
Chapter 5: Conclusion	79
Chapter 6: Supplemental Information	81
References	82
Additional Resources	84
Appendix A. Quantitative Measurement Procedures and the Property of Linearity	85
Appendix B. Design of Linearity Study Through Mixing HIGH and LOW Sample Pools	88
Appendix C. Linearity Panel Preparation Schemes	94
Appendix D. Number of Replicates for a Linearity Interval Study	105
Appendix E. Weighted and Ordinary Least Squares Linear Regressions	108
Appendix F. Worksheets of Calculations for Linear Regression Analysis	113
Appendix G. An Example of a Linearity Study With Two Replicates	117
Appendix H. An Example of a Linearity Study With Two (or More) Sets of Panel Members	123
Appendix I. An Example of a Linearity Study Using Samples With Assigned Values	131
Appendix J. Consideration of Low and High Sample Concentrations in the Verification Study	135
The Quality Management System Approach	138
Related CLSI Reference Materials	139

Foreword

A measurement procedure is **linear throughout a given interval** when, in that interval, the measured results “on average” (ie, abstracting from imprecision) are **proportional** to the measurand’s true quantity values, meaning that the measurand results agree with the true values up to a constant multiplicative factor:

$$\text{Measured value} = k(\text{True value}) \quad (k > 0) \quad (1)$$

A measurement procedure is **linear** (without additional qualification) when the procedure is linear throughout its stated analytical measuring interval. Thus, for example, in patient monitoring, when a measurand’s true value doubles or decreases by 15% from one sample to the next, results obtained using a measurement procedure demonstrated to be linear can be expected (within limits determined largely by imprecision) to respectively double or decrease by 15%, although the procedure might exhibit systematic proportional bias relative to the measurand’s true quantity values.

This characterization of linearity applies not only to measurement procedures that report results in concentration units (eg, nmol/L, ng/dL, $\mu\text{IU/mL}$), but also to those reporting enzyme activity, blood cell counts, etc. (For brevity, this guideline is written as if all such assays report in concentration units.) However, some tests reporting on a continuous scale, such as tests measuring specific patient (auto)antibodies, cannot be expected to show linear behavior for all patient samples. Moreover, the characterization is consistent with the use of “linear” and cognate terms in clinical chemistry as applied to conventional linearity-under-dilution studies. These studies typically involve preparing a spectrum of mixtures by combining a high-concentration sample with a measurand-free sample (or diluent), generating and averaging replicate measurement results for each mixture, and finally regressing these results vs the values expected from the high sample proportion (ie, relative volume) represented in each mixture. Success is demonstrated when, analytically and/or graphically, the paired values (ie, observed and expected results) all closely approximate a straight-line trajectory passing through the origin (0,0), making appropriate allowance for the measurement procedure’s imprecision, the experiment’s size, and clinically acceptable measurand- and concentration-specific deviations from the line.

The approach advocated in this edition of EP06, as well as previous editions, can be regarded as refinements of this conventional study with respect to design, analysis, and interpretation.

Overview of Changes

This guideline replaces the previous edition of the approved guideline, EP06-A, published in 2003.

The first edition, EP06-P, published in October 1986, relied on fitting a straight line to measurements of five equally spaced samples, four replicates each, judging linearity by a goodness-of-fit test based on comparing dispersion around the regression line with the repeatability (ie, within-run imprecision) exhibited in the experiment. Unfortunately, this statistical test puts measurement procedures with excellent repeatability at risk of inappropriately failing. Conversely, it might fail to identify nonlinearity in measurement procedures with very poor repeatability.

To rectify this shortcoming, the second edition, EP06-P2, published in December 2001, and the first approved guideline, EP06-A, published in April 2003, adopted a different and computationally more complex statistical test for linearity. EP06-A called for fitting not only first-order but also second- and third-order polynomials (ie, linear, quadratic, and cubic models) to the data, judging the measurement procedure to be linear if, by internal statistical criteria, the first-order fit is best. In effect, EP06-A asked whether the trajectory of experimental results had a shape more closely resembling a straight line rather than a parabolic or sigmoidal curve. Unfortunately, this method placed no restriction on the trajectory’s orientation. EP06-A, unlike major publications cited therein, was not sufficiently clear that, with suitable

allowance for random error, the trajectory should be aligned with the origin. (Intuitively, for example, a measurement procedure exhibiting little or no decrease in measured results under progressive dilutions, such as so-called “analog” procedures for free thyroxine, is not considered linear even when the trajectory of results approximates a straight-line segment.)

This edition of EP06 builds on the previous editions, introducing several important refinements, including:

- The discussion of dilution schemes, designed to minimize errors in preparing the test panels, has been extended. There is no longer any suggestion that samples need to be equally spaced. This guideline encourages judicious interpolation of additional mixtures to improve coverage of concentration gaps between calibrators, as well as concentrations important for decision-making or monitoring.
- Like EP06-A, this edition emphasizes that suitable visualizations of the study data are important, and many examples are provided.
- Consistent with other CLSI method evaluation guidelines, this guideline calls for judging results in terms of the clinical acceptability of deviations (ie, deviations from linearity at each of the sample concentrations), as opposed to a global pass-or-fail assessment based solely on internal statistical criteria. This point of view makes this guideline’s approach more relevant to clinical practice and more informative as to the location, magnitude, and significance of any deviations from linearity.
- Chapter 3 is devoted to validating linearity (intended for manufacturers and developers), and Chapter 4 covers verifying (ie, spot-checking) linearity (intended for end-user laboratories).
- Two study designs are discussed: one study design includes a high sample (whose concentration is known to exceed the procedure’s analytical measuring interval) and a measurand-free sample. The other study design includes high and low samples with known concentrations or a known concentration ratio. These designs serve different purposes, have different limitations, and use somewhat different data analyses.
- Computationally, this edition’s approach is simpler than that of EP06-A, insofar as fitting second- and third-order polynomials is no longer included for validating or verifying linearity (although developers might find such analysis informative). Conversely, weighted first-order regression analysis is recommended under appropriate circumstances to limit the risk of failure due to chance. Advice is provided on determining adequate sample-specific weights in the absence of a precision profile.
- The importance of stating a performance claim is emphasized.

NOTE: The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

KEY WORDS

Linearity

Measurement error

Weighted linear regression

Measured values

Proportionality

Chapter 1

Introduction

This chapter includes:

- Guideline's scope and applicable exclusions
- Background information pertinent to the guideline's content
- Standard precautions information
- Terminology information, including:
 - Terms and definitions used in the guideline
 - Abbreviations and acronyms used in the guideline

Evaluation of Linearity of Quantitative Measurement Procedures

1 Introduction

1.1 Scope

This guideline provides recommendations for designing, analyzing, and interpreting linearity studies for quantitative measurement procedures. This guideline is intended for manufacturers and developers seeking to validate the linearity of a measurement procedure throughout a stated concentration interval, especially the interval that includes the measurement procedure's lower limit of quantitation (LLOQ) and upper limit of quantitation (ULOQ). It is also intended for laboratorians who verify the linearity of a measurement procedure and for regulatory agencies responsible for overseeing *in vitro* diagnostic (IVD) manufacturers or end-user laboratories.

This guideline does not include information on linearity issues encountered during the measurement procedure development phase, such as efficiently identifying the widest possible interval for a linearity claim or selecting calibration points, although the experimental design and data analysis principles described herein can be of value during that phase.

Before the laboratory begins formal linearity verification studies, the measurement procedure's intended analytical measuring interval claim should already have been determined based on the results of linearity, precision, and other studies that have been evaluated using a clinically informed error budget for imprecision, bias, etc.

1.2 Background

EP06 is one of the CLSI method evaluation documents, which provide guidance on experimental evaluation of quantitative measurement procedures. These documents describe studies covering, eg, precision (see CLSI documents EP05¹ and EP15²), measurement procedure comparison and bias (see CLSI document EP09³), recovery (see CLSI document EP15²), and limits of quantitation (see CLSI document EP17⁴). EP06 is devoted to linearity studies.

The recommendations in this guideline differ depending on whether the study is intended to validate a measurement procedure's linearity or merely to verify it and also on whether fully commutable, measurand-free material is available for use as a diluent.

For verification, practical considerations may necessitate a smaller, less rigorous study than would be required to validate performance claims for regulatory purposes. For example, compared with validation, verification may involve fewer samples (ie, mixtures, dilutions), fewer replicates, and often, for at least two reasons, sample concentrations that span only a large segment of the measurement procedure's stated analytical measuring interval. First, owing to software constraints, end users might not be able to generate explicit numerical results for samples with concentrations beyond the upper and/or lower limits of the procedure's analytical measuring interval. Moreover, owing to the procedure's inherent imprecision, laboratories might not be able to generate consistent results for samples very close to (but within) these limits. Second, to accommodate multiple commercial measurement procedures for a given measurand that differ in their stated analytical measuring intervals, third-party providers of samples for linearity (or calibration) verification studies sometimes restrict the samples' concentration span for that measurand to an interval deemed medically essential for any such procedure.